CSIMarket
 
Esperion Therapeutics Inc   (NASDAQ: ESPR)
Other Ticker:  
 
 
Price: $1.8700 $-0.01 -0.532%
Day's High: $1.905 Week Perf: 0.54 %
Day's Low: $ 1.84 30 Day Perf: -16.52 %
Volume (M): 2,006 52 Wk High: $ 3.94
Volume (M$): $ 3,750 52 Wk Avg: $2.21
Open: $1.89 52 Wk Low: $1.58



 Market Capitalization (Millions $) 365
 Shares Outstanding (Millions) 195
 Employees 70
 Revenues (TTM) (Millions $) 295
 Net Income (TTM) (Millions $) -87
 Cash Flow (TTM) (Millions $) 30
 Capital Exp. (TTM) (Millions $) 0

Esperion Therapeutics Inc
Esperion Therapeutics Inc. is a biopharmaceutical company based in the United States that specializes in developing and commercializing innovative therapies for the treatment of cardiovascular diseases. The company's primary focus is on developing oral, targeted therapies designed to lower elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, a condition associated with an increased risk of cardiovascular disease. Esperion Therapeutics' lead product candidate is bempedoic acid, which has shown promising results in lowering LDL-C levels and improving cardiovascular outcomes in clinical trials. The company is committed to addressing the unmet medical needs of patients and aims to provide safe and effective therapeutic options for the prevention and treatment of cardiovascular diseases.


   Company Address: 3891 Ranchero Drive, Suite 150 Ann Arbor 48108 MI
   Company Phone Number: 887-3903   Stock Exchange / Ticker: NASDAQ ESPR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        2.21% 
BMY   -0.53%    
JNJ        1.55% 
LLY   -0.02%    
MRK   -3.53%    
PFE   -1.33%    
• View Complete Report
   



Management Announcement

Esperion Therapeutics: Navigating a New Financial Horizon Amid Market Uncertainty

Published Wed, Dec 18 2024 12:00 PM UTC

As the biotechnology sector continues to navigate the turbulent seas of market volatility, few companies exemplify this challenge like Esperion Therapeutics Inc. (NASDAQ: ESPR). In its latest financial maneuvers, the company has caught the attention of investors and analysts alike with its proactive steps to strengthen its balance sheet. Esperion, focused on developing innov...

Stocks on the Move

Esperion Therapeutics Balancing Promise and Performance Amidst Market Turbulence,

Published Mon, Dec 16 2024 8:52 PM UTC

Navigating the Ups and Downs: The Rollercoaster Journey of Esperion TherapeuticsEsperion Therapeutics Inc. (NASDAQ: ESPR) is a biotechnology company focused on developing and commercializing innovative therapies for patients with cardiovascular diseases. Recently, shares of Esperion have experienced significant fluctuations, sparking interest and concern among investors. As...

Product Service News

Esperion Therapeutics Championing Growth and Global Collaboration in Cholesterol Management,

Published Thu, Dec 12 2024 1:01 PM UTC

Esperion Therapeutics: Innovative Growth and Strategic Partnerships In a rapidly evolving pharmaceutical landscape, Esperion Therapeutics Inc. has stood out as a noteworthy success story in recent times. With a burgeoning interest in innovative solutions for cholesterol management, the company has successfully aligned itself with strategic global partnerships and achieved ad...

Stock Market Announcement

Esperion Grants Thousands of Restricted Stock Units to New Employees as Part of Growth Strategy,

Published Fri, Nov 8 2024 9:15 PM UTC

Esperion Continues to Bolster Workforce with Restricted Stock Unit Grants Amid Strategic GrowthBy Author Name November 8, 2024 In a strategic move indicative of its ongoing commitment to attract and retain top talent, Esperion Therapeutics, Inc. (NASDAQ: ESPR), headquartered in Ann Arbor, Michigan, has announced the awarding of a significant number of restricted stock ...

Shares

Esperion Therapeutics Grants Restricted Stock Units to New Employees Amid Royalties Monetization Deal,

Published Wed, Sep 25 2024 8:30 PM UTC

Esperion Therapeutics Bolsters Workforce with Restricted Stock Units Amid Recent Royalty MonetizationIn a strategic move to enhance its talent pool, Esperion Therapeutics, a biopharmaceutical company based in Ann Arbor, Michigan, has announced the grant of 3,500 restricted stock units (RSUs) to a new employee as part of its 2017 Inducement Equity Incentive Plan. This announc...







Esperion Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com